360 research outputs found
Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review
The use of symptomatic agents has greatly improved the medical treatment of advanced
cancer patients with inoperable bowel obstruction. A systematic review of studies of the most popular drugs used in the medical management of inoperable malignant bowel obstruction was performed to assess the effectiveness of these treatments and provide some lines of evidence. Randomized trials that involved patients with a clinical diagnosis of intestinal obstruction due to advanced cancer treated with these drugs were reviewed. Five reports fulfilled inclusion criteria. Three studies compared octreotide (OC) and hyoscine
butylbromide (HB), and two studies compared corticosteroids (CSs) and placebo. Globally, 52
patients received OC, 51 patients received HB, 37 patients received CSs, 15 patients received
placebo, and 37 patients received both placebo and CSs. On the basis of these few data, the
superiority of OC over HB in relieving gastrointestinal symptoms was evidenced in a total of 103 patients. The latter studies had samples more defined in terms of stage and inoperability, and had a shorter survival in comparison with studies of CSs (less than 61 days, most of them less than 20 days). Data on CSs are less convincing, due to the methodological weakness of existing studies. This review confirms the difficulties in conducting randomized controlled trials in this population
The use of opioids in the last week of life in an acute palliative care unit.
The aim of this survey was to assess the opioid use in the last week of life of cancer patients admitted at an acute palliative care unit. From a consecutive sample of patients surveyed for a period of one year, patients who died in the unit were selected. Type of opioid, route of administration, and doses were recorded one week before death (or at admission time if the interval admission-death was less than one week) (-7), and on the day of death (Tend). Seventy-seven patients died in the unit in the period taken into consideration (12.4%). Oral morphine equivalents were 170 mg/day and 262 mg/day at -7 and Tend, respectively. Patients were receiving transdermal drugs or intravenous morphine at Tend, with a trend in the use of intravenous morphine at Tend (p=0.07). Intravenous morphine was more frequently used in sedated patients at Tend (p=0.015).No differences in age, gender, opioid doses, and OEI were found among opioids used. In patients who were sedated doses of opioids were significantly increased (p=0.012). In the last week of life intravenous morphine is the preferred modality to deliver opioids in an acute palliative care unit. Doses increases prevalently observed in sedated patients were performed before starting sedation with the purpose to treat concomitant distressing symptoms, such as dyspnoea
Effectiveness and tolerability of amidotrizoate for the treatment of constipation resistant to laxatives in advanced cancer patients.
Trends in epidemiology: the role of denominator fluctuation in population based estimates
Population estimates are of paramount importance for calculating occurrence and association measures although they can be affected by problems of accuracy and completeness. This study has performed a simulation of the impact of Italian population size variability on incidence rates
Opioid-induced or pain relief-reduced symptoms in advanced cancer patients?
Background: While opioids in increasing doses may produce adverse effects, the same adverse effects may be associated with poor pain control. Moreover, in the clinical setting symptomatic treatment and illness may balance the outcome of opioid titration. Some adverse effects may tend to disappear continuing the treatment in a long-term period.
Aims: The aim of this study was to monitor the effects of a rapid opioid titration combined with symptomatic treatment in patients
with poor relief and to monitor these changes in the following period of 20 days.
Methods: A consecutive sample of 35 patients admitted to an acute Pain Relief and Palliative Care Unit were titrated with opioids,
according to a department policy, allowing administration of parenteral opioids to assist opioid titration with oral or transdermal
opioids.
Results: Thirty-three patients were followed up for the period of the study. Pain was adequately controlled and doses were opioid doses were stable after a mean of 40 h. Opioid escalation index (OEI) was extremely high initially, and then progressively declined at the following study intervals. Weakness and nausea and vomiting did not change, as well as confusion and appetite. Drowsiness, constipation and dry mouth significantly increased and then did not change, although a significant decrease in drowsiness was subsequently observed. Well-being improved some weeks after opioid stabilization. In multivariate analysis, drowsiness and dry mouth were correlated to opioid doses.
Conclusion: The effects reported were often due to multiple causes. A rapid decrease in pain intensity induced by rapid opioid titration
does not produce changes in weakness, nausea and vomiting, appetite. While constipation appears the most relevant problem,resistant to common symptomatic treatment, drowsiness initially produced by acute opioid dose increase and the achievement of pain relief, tends to spontaneously decrease, probably as the result of late tolerance. Improved well-being may be the late positive effect of pain relief, also influenced by the setting of home care
Rapid switching between transdermal fentanyl and methadone in cancer patients
Purpose
The aim of this study was to examine the clinical effects of switching from transdermal (TTS)fentanyl to methadone, or vice versa, in patients with a poor response to the previous opioid.
Patients and Methods
A prospective study was carried out on 31 patients who switched from TTS fentanyl to oral
methadone, or vice versa, because of poor opioid response. A fixed conversion ratio of
fentanyl to methadone of 1:20 was started and assisted by rescue doses of opioids, and then
doses were changed according to clinical response. Pain and symptom intensity, expressed
as distress score, were recorded before switching doses of the two opioids and after
subsequent doses. The number of changes of the daily doses, time to achieve stabilization,
and hospital stay were also recorded.
Results
Eighteen patients were switched from TTS fentanyl to methadone, and seven patients were
switched from methadone to TTS fentanyl. A significant decrease in pain and symptom
intensity, expressed as symptom distress score, was found within 24 hours after switching
took place in both directions. Unsuccessful switching occurred in six patients, who were
subsequently treated with an alternative therapy.
Conclusion
A rapid switching using an initial fixed ratio of fentanyl to methadone of 1:20 is an effective
method to improve the balance between analgesia and adverse effects in cancer patients
with poor response to the previous opioid. No relationship between the final opioid dose and
the dose of the previous opioid has been found
Opioid-induced hyperalgesia after rapid titration with intravenous morphine: Switching and re-titration to intravenous methadone
Rapid titration with intravenous morphine (IV-MO) provides fast and efficient pain relief in cancer patients with severe-excruciating pain. However, some patients, after an initially favourable response, can develop an hyperexcitated state unrelieved or worsened by further dose increments
- …